Projects per year
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
-
-
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
Pasqualini, R. (CoPI), Libutti, S. (CoPI) & Arap, W. (CoPI)
3/15/20 → 2/28/25
Project: Research project
-
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors
Zamboni, W. C. (PI), Chang, S. S. X. (CoPI) & Libutti, S. (CoPI)
4/1/21 → 3/31/24
Project: Research project
-
Rutgers Optimizes Innovation (ROI) Program
Panettieri, R. R. A., Pasqualini, R., Libutti, S. S. K., Kohn, J. B. & Libutti, S.
National Heart, Lung, and Blood Institute
9/23/19 → 8/31/23
Project: Research project
-
Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management
Davis, C. H., Laird, A. M. & Libutti, S. K., 2024, In: Baylor University Medical Center Proceedings. 37, 1, p. 104-110 7 p.Research output: Contribution to journal › Article › peer-review
-
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection
Singla, A., Dadario, N. B., Singla, A., Greenberg, P., Yan, R., Nanda, A., Boison, D., Malhotra, R., Patel, S., Nipun, S., Maninderpal, K., Castro, D., Bdiiwi, S., Boktor, H., Kyi, H. H., Sutherland, A., Patrawalla, A., Ly, K., Xie, Y. & Sonig, A. & 6 others, , Jan 2023, In: PLoS One. 18, 1 January, e0274243.Research output: Contribution to journal › Article › peer-review
Open Access -
Rutgers Cancer Institute of New Jersey’s Community Outreach and Engagement Approach to Cancer Prevention
Kinney, A. Y., Stroup, A. M., Scharf, S. & Libutti, S. K., Nov 2023, In: Cancer Prevention Research. 16, 11, p. 595-600 6 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Amino acids control blood glucose levels through mTOR signaling
Fan, J., Yuan, Z., Burley, S. K., Libutti, S. K. & Zheng, X. F. S., Aug 2022, In: European Journal of Cell Biology. 101, 3, 151240.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Rajdev, L., Lee, J. W., Libutti, S. K., Benson, A. B., Fisher, G. A., Kunz, P. L., Hendifar, A. E., Catalano, P. & O’Dwyer, P. J., Dec 2022, In: Investigational New Drugs. 40, 6, p. 1306-1314 9 p.Research output: Contribution to journal › Article › peer-review
Open Access